GoodRx (NASDAQ:GDRX) Announces Earnings Results

GoodRx (NASDAQ:GDRX) posted its earnings results on Wednesday. The company reported $0.08 EPS for the quarter, hitting analysts’ consensus estimates of $0.08, FiscalAI reports. The company had revenue of $200.41 million for the quarter, compared to the consensus estimate of $194.56 million. GoodRx had a return on equity of 7.32% and a net margin of 2.07%.The firm’s revenue for the quarter was down 1.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.09 earnings per share.

GoodRx Price Performance

Shares of GDRX stock traded up $0.01 during mid-day trading on Friday, hitting $3.73. 1,397,472 shares of the stock were exchanged, compared to its average volume of 2,110,426. GoodRx has a 52-week low of $1.77 and a 52-week high of $5.81. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.78. The company has a market cap of $1.28 billion, a PE ratio of 93.15, a price-to-earnings-growth ratio of 1.51 and a beta of 1.60. The firm has a fifty day moving average of $2.93 and a 200 day moving average of $2.54.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC boosted its holdings in GoodRx by 903.3% in the 4th quarter. Virtu Financial LLC now owns 133,886 shares of the company’s stock worth $363,000 after buying an additional 120,542 shares during the last quarter. Invesco Ltd. lifted its position in shares of GoodRx by 48.8% in the fourth quarter. Invesco Ltd. now owns 186,534 shares of the company’s stock valued at $506,000 after acquiring an additional 61,193 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of GoodRx in the fourth quarter worth approximately $51,000. EP Wealth Advisors LLC purchased a new position in GoodRx in the 4th quarter valued at $44,000. Finally, Mackenzie Financial Corp acquired a new stake in GoodRx during the 4th quarter worth $1,009,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Weiss Ratings downgraded shares of GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, July 23rd. TD Cowen boosted their price objective on GoodRx from $3.00 to $4.00 and gave the company a “buy” rating in a report on Monday, May 11th. Citigroup reaffirmed a “buy” rating on shares of GoodRx in a research report on Thursday, July 23rd. The Goldman Sachs Group reiterated a “neutral” rating and issued a $4.00 target price on shares of GoodRx in a research note on Friday. Finally, Wells Fargo & Company raised their price target on GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $4.15.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.